Previous Close | 12.96 |
Open | 12.95 |
Bid | 12.58 x 1200 |
Ask | 13.02 x 1000 |
Day's Range | 12.74 - 13.10 |
52 Week Range | 11.57 - 20.71 |
Volume | |
Avg. Volume | 624,181 |
Market Cap | 893.225M |
Beta (5Y Monthly) | 0.54 |
PE Ratio (TTM) | 5.64 |
EPS (TTM) | 2.27 |
Earnings Date | Feb 07, 2023 - Feb 13, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | Sep 08, 2015 |
1y Target Est | 17.50 |
In this article, we discuss 12 most undervalued pharma stocks to buy according to hedge funds. If you want to see more stocks in this selection, check out 5 Most Undervalued Pharma Stocks To Buy According To Hedge Funds. Fitch Ratings has assigned a ‘Neutral’ outlook to the global pharmaceutical and biotech sector, indicating Fitch’s […]
Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that it has closed a secured convertible credit agreement (the "credit agreement") with Innoviva Strategic Opportunities LLC, a wholly-owned subsidiary of Innoviva, Inc. (Nasdaq: INVA) (collectively, "Innoviva"), Armata's largest shareholder. The gross p
In the latest trading session, Innoviva (INVA) closed at $13.27, marking a +0.15% move from the previous day.